Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam in ICU during COVID-19
NCT04611425Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remimazolam in acute respiratory failure (ARF) and coronavirus disease 2019 (COVID-19), sponsored by CHU de Nantes. Primary endpoint: Composite endpoint including a combination of cardio-vascular and sedation events at 8 hours. Started Nov 2020; status: completed.
02
Drugs
remimazolam
03
Conditions
acute respiratory failure (ARF)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04611425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611425.